Drug Trial Radar · NCT01585558
Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus
Last checked: Nov 20, 2026Latest source record: May 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
May 16, 2006
Primary completion
Aug 19, 2008
Study completion Sep 18, 2008
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- Collaborators
- QuatRx Pharmaceuticals
- First posted
- Apr 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study was to assess the long-term safety of 30- and 60-mg daily doses of ospemifene in the treatment of Vulvar and Vaginal Atrophy (VVA) in postmenopausal women with an intact uterus.
Conditions
- Atrophy
- Vaginal Diseases
Interventions
Ospemifene (Dose 1)Drug
Ospemifene (Dose 2)Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: Week 20 (Phone Contact) to Week 56 (Visit 7)
- Assessment of Cervical Pap Smear SamplesTime frame: Week 52 (Visit 6)
- Assessment of Endometrial BiopsyTime frame: Week 52 (Visit 6)
- Mean Percent Change From Baseline in Serum LipidsTime frame: Baseline to Week 26 (Visit 5)
- Mean Percent Change From Baseline in Serum LipidsTime frame: Baseline to Week 52 (Visit 6)
- Mean Change in Blood Chemistry ParametersTime frame: Baseline to Week 26 (Visit 5)
- Mean Change in Blood Chemistry ParametersTime frame: Baseline to Week 52 (Visit 6)
- Assessment of Endometrial Safety With a Transvaginal Ultrasound (TVU)Time frame: Baseline to Week 26 (Visit 5)
- Assessment of Endometrial Safety With a TVUTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in Visual Evaluation of the VaginaTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Visual Evaluation of the VaginaTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in Estradiol (E2) LevelsTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Luteinizing Hormone (LH) LevelsTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Follicle Stimulating Hormone (FSH) LevelsTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Sex Hormone Binding Globulin (SHBG) LevelsTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Testosterone (Total) LevelsTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Testosterone (Free) LevelsTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in E2 LevelsTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in LH LevelsTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in FSH LevelsTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in SHBG LevelsTime frame: Baseline to Week 52 (Visit 6)
- Assessment of MammographyTime frame: Week 52 (Visit 6)
- Change From Baseline in Testosterone (Total) LevelsTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in Testosterone (Free) LevelsTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in Antithrombin Antigen, P LevelsTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Fibrinogen LevelsTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Protein C Ag, P LevelsTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Protein S Ag (Free), P LevelsTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Thromboplastin TimeTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Antithrombin Antigen, P LevelsTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in Fibrinogen LevelsTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in Protein C Ag, P LevelsTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in Protein S Ag (Free), P LevelsTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in Thromboplastin TimeTime frame: Baseline to Week 52 (Visit 6)
- Assessment of Breast PalpationTime frame: Week 26 (Visit 5)
- Assessment of Breast PalpationTime frame: Week 52 (Visit 6)
- Assessment of Hematology TestsTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Erythrocyte (RBC) LevelsTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Hemogobin LevelsTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Hematocrit LevelsTime frame: Baseline to Week 26 (Visit 5)
- Assessment of Hematology Test ValuesTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in Erythrocyte (RBC) LevelsTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in Hemoglobin LevelsTime frame: Baseine to Week 52 (Visit 6)
- Change From Baseline in Hematocrit LevelsTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in pH of UrineTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Specific Gravtiy of UrineTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in pH of UrineTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in Specific Gravity of UrineTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in Systolic Blood Pressure (SBP)Time frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Diastolic Blood Pressure (DBP)Time frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in Pulse RateTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in WeightTime frame: Baseline to Week 26 (Visit 5)
- Change From Baseline in BMITime frame: Baseline to Week 26
- Change From Baseline in SBPTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in DBPTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in Pulse RateTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in WeightTime frame: Baseline to Week 52 (Visit 6)
- Change From Baseline in BMITime frame: Baseline to Week 52 (Visit 6)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.